AstraZeneca (NYSE:AZN) Share Price Breaks Above 200-Day Moving Average – Should You Sell?

AstraZeneca Plc (NYSE:AZN) passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $180.21 and traded as high as $188.39. AstraZeneca shares last traded at $186.49, with a volume of 5,464,384 shares trading hands.

Trending Headlines about AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research reports. Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Nordea Equity Research upgraded shares of AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Wall Street Zen raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Finally, CICC Research initiated coverage on shares of AstraZeneca in a research note on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective for the company. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Trading Up 6.9%

The firm has a fifty day moving average of $164.48 and a 200 day moving average of $180.21. The firm has a market capitalization of $289.23 billion, a PE ratio of 26.38, a P/E/G ratio of 1.45 and a beta of 0.27. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $16.21 billion during the quarter, compared to analysts’ expectations of $16 billion. During the same quarter in the prior year, the business earned $2.38 EPS. AstraZeneca’s quarterly revenue was up 6.5% compared to the same quarter last year. Equities research analysts expect that AstraZeneca Plc will post 10.21 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Professional Advisory Services Inc. purchased a new position in AstraZeneca in the second quarter valued at about $30,241,000. Wealthcare Advisory Partners LLC acquired a new position in AstraZeneca in the 2nd quarter worth about $2,296,000. Andra AP fonden raised its stake in shares of AstraZeneca by 122.9% during the 2nd quarter. Andra AP fonden now owns 526,714 shares of the company’s stock worth $99,876,000 after purchasing an additional 290,412 shares in the last quarter. Westport Asset Management Inc. purchased a new stake in shares of AstraZeneca during the 2nd quarter worth about $1,422,000. Finally, Madison Asset Management LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter valued at about $4,041,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.